MX2014007188A - Subpoblación de monocitos humanos para el tratamiento de daños al sistema nervioso central. - Google Patents

Subpoblación de monocitos humanos para el tratamiento de daños al sistema nervioso central.

Info

Publication number
MX2014007188A
MX2014007188A MX2014007188A MX2014007188A MX2014007188A MX 2014007188 A MX2014007188 A MX 2014007188A MX 2014007188 A MX2014007188 A MX 2014007188A MX 2014007188 A MX2014007188 A MX 2014007188A MX 2014007188 A MX2014007188 A MX 2014007188A
Authority
MX
Mexico
Prior art keywords
treatment
population
nervous system
central nervous
human monocyte
Prior art date
Application number
MX2014007188A
Other languages
English (en)
Other versions
MX358589B (es
Inventor
Michal Eisenbach-Schwartz
Ester Yoles
Ravid Shechter
Omer Miller
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MX2014007188A publication Critical patent/MX2014007188A/es
Publication of MX358589B publication Critical patent/MX358589B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee una subpoblación de células mononucleares de sangre periférica (PBMC) que está sustancialmente libre de células CD3+, células CD19+, células CD56+ y opcionalmente de células CD16+, para usarse en el tratamiento de daños al SNC.
MX2014007188A 2011-12-14 2012-12-13 Subpoblación de monocitos humanos para el tratamiento de daños al sistema nervioso central. MX358589B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161570593P 2011-12-14 2011-12-14
PCT/IL2012/050522 WO2013088441A1 (en) 2011-12-14 2012-12-13 Human monocyte sub-population for treatment of central nervous system injury

Publications (2)

Publication Number Publication Date
MX2014007188A true MX2014007188A (es) 2015-09-22
MX358589B MX358589B (es) 2018-08-27

Family

ID=48611950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007188A MX358589B (es) 2011-12-14 2012-12-13 Subpoblación de monocitos humanos para el tratamiento de daños al sistema nervioso central.

Country Status (15)

Country Link
US (1) US9314483B2 (es)
EP (1) EP2790712B1 (es)
JP (1) JP6148679B2 (es)
KR (1) KR20140107439A (es)
CN (1) CN104159590A (es)
AU (2) AU2012354057B2 (es)
BR (1) BR112014014560A8 (es)
DK (1) DK2790712T3 (es)
ES (1) ES2604356T3 (es)
HU (1) HUE032096T2 (es)
IN (1) IN2014MN01420A (es)
MX (1) MX358589B (es)
PL (1) PL2790712T3 (es)
PT (1) PT2790712T (es)
WO (1) WO2013088441A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971039B1 (en) 2013-03-14 2020-01-01 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
CN105377273A (zh) * 2013-05-22 2016-03-02 耶达研究与发展公司 用于治疗眼睛疾病或病症的人类单核细胞亚群
EP4177336A1 (en) * 2014-12-19 2023-05-10 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
US10722529B2 (en) 2015-12-03 2020-07-28 Temple University—Of the Commonwealth System of Higher Education Modulation of NAD+ metabolic pathways for treatment of disease
WO2020148769A1 (en) * 2019-01-16 2020-07-23 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Biomarker for cns disease modification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800812A (en) 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
WO1998005795A1 (en) * 1996-08-02 1998-02-12 The Center For Blood Research, Inc. Enrichment of dendritic cells from blood
US6267995B1 (en) 1999-03-03 2001-07-31 Pure World Botanicals, Inc. Extract of Lepidium meyenii roots for pharmaceutical applications
KR20100087781A (ko) * 2001-11-21 2010-08-05 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 인간 단핵 식세포성 백혈구의 제조 방법
EP2282748B1 (en) * 2008-03-28 2016-11-09 Stemcyte, Inc. Treatment of brain damage using umbilical cord blood cells
CN105377273A (zh) * 2013-05-22 2016-03-02 耶达研究与发展公司 用于治疗眼睛疾病或病症的人类单核细胞亚群

Also Published As

Publication number Publication date
JP6148679B2 (ja) 2017-06-14
KR20140107439A (ko) 2014-09-04
AU2012354057B2 (en) 2017-08-03
DK2790712T3 (en) 2016-12-19
US20140363411A1 (en) 2014-12-11
AU2017254830A1 (en) 2017-11-16
BR112014014560A8 (pt) 2017-07-04
EP2790712A4 (en) 2015-06-24
US9314483B2 (en) 2016-04-19
HUE032096T2 (en) 2017-09-28
WO2013088441A1 (en) 2013-06-20
AU2012354057A1 (en) 2014-07-31
PL2790712T3 (pl) 2017-04-28
BR112014014560A2 (pt) 2017-06-13
PT2790712T (pt) 2016-12-02
ES2604356T3 (es) 2017-03-06
EP2790712B1 (en) 2016-08-31
MX358589B (es) 2018-08-27
IN2014MN01420A (es) 2015-04-03
CN104159590A (zh) 2014-11-19
JP2015501835A (ja) 2015-01-19
EP2790712A1 (en) 2014-10-22

Similar Documents

Publication Publication Date Title
MX358589B (es) Subpoblación de monocitos humanos para el tratamiento de daños al sistema nervioso central.
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2013006595A (es) Tratamiento de lesion de la medula espinal y lesion traumatica del cerebro empleando celulas madre placentarias.
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
MY163057A (en) Means and methods for trating dlblcl
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
MY185016A (en) Progenitor cells of mesodermal lineage
CR20120404A (es) Proteinas de enlace cd127
SG178991A1 (en) Anti-gitr antibodies
PH12015500276A1 (en) Treatment of immune-related and inflammatory diseases
PH12014501613A1 (en) Anti-asic1 antibodies and uses thereof
WO2012054792A3 (en) Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells
MA38193A1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
PL399447A1 (pl) Szczepionka do leczenia cukrzycy typu 1 u dzieci, zastosowanie sortera komórek oraz sposób namnazania komórek Treg do wytwarzania szczepionki do leczenia cukrzycy typu 1
MX2015008190A (es) Tretaspanina 33 es una candidata para la terapia dirigida de anticuerpos para el tratamiento de linfomas de hodgkin de linfocitos b.
MX2015016062A (es) Sub-poblacion de monocitos humanos para el tratamiento de enfermedades y trastornos del ojo.
WO2012009640A3 (en) B cell depletion for central nervous system injuries and methods and uses thereof
FR2999932B1 (fr) Utilisation de microorganismes probiotiques comme agent favorisant la synthese de melanine
UA59907U (ru) Способ индивидуального подбора антиэпилептических препаратов для лечения эпилепсий
GB2497255A (en) Dice
RU2010142344A (ru) Способ исследования безусловного рефлекса детей первых месяцев жизни - реакция выпрямления ног
UA72171U (ru) Способ прогнозирования последствий оплодотворения in vitro и переноса эмбрионов
UA66222U (ru) Способ определения риска развития вторичных опухолей у больных хронической лимфоцитарной лейкемией, которые испытали влияние ионизирующего излучения
SG169915A1 (en) A nuclear receptor and the use of the same in the reprogramming of cells

Legal Events

Date Code Title Description
FG Grant or registration